Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Revisiting systemic treatment of bacterial endophthalmitis: a review of intravitreal penetration of systemic antibiotics
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 4499320
Author(s) Brockhaus, Lisa; Goldblum, David; Eggenschwiler, Laura; Zimmerli, Stefan; Marzolini, Catia
Author(s) at UniBasel Marzolini, Catia
Year 2019
Title Revisiting systemic treatment of bacterial endophthalmitis: a review of intravitreal penetration of systemic antibiotics
Journal Clinical microbiology and infection
Pages / Article-Number NA
Abstract Adjunctive systemic antibiotic therapy for treatment of bacterial endophthalmitis is controversial but common practice due to the severity of the disease. In absence of guidance documents, several antibiotic regimens are being used without applying evidence-based prescribing, thus leading to inappropriate treatment of this serious eye condition.; To summarize available data on intravitreal penetration of systemically administered antibiotics and to discuss their usefulness from a microbiological and pharmacological point of view.; We performed a systematic PubMed search of studies investigating antibiotic concentrations in the vitreous after systemic administration in humans, and selected animal models.; The best-documented agents achieving therapeutic levels in the vitreous are meropenem, linezolid and moxifloxacin. Vancomycin, cefazoline, ceftriaxone, ceftazidime, imipenem and trimethoprim-sulfamethoxazole reach levels justifying their use in specific situations. Available data do not support the use of ciprofloxacin, levofloxacin, aminoglycosides, aminopenicillins, piperacillin, cefepime, and clarithromycin. With very limited but available promising data, the use of daptomycin and rifampicin deserves further investigation.; The choice of the adjunctive systemic antibiotic agent - in situations where considered relevant for treatment - must to date be made on an individual base, considering microbiological aspects as well as operative status and inflammation of the eye. This review gives a systematic overview of antibiotic options and provides guidance to the clinician striving for optimal systemic antibiotic treatment of bacterial endophthalmitis.
Publisher Elsevier
ISSN/ISBN 1198-743X ; 1469-0691
URL https://www.ncbi.nlm.nih.gov/pubmed/30771529
edoc-URL https://edoc.unibas.ch/69626/
Full Text on edoc Available
Digital Object Identifier DOI 10.1016/j.cmi.2019.01.017
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/30771529
ISI-Number MEDLINE:30771529
Document type (ISI) Journal Article, Review
 
   

MCSS v5.8 PRO. 0.359 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
27/04/2024